Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer

Sushil K. Badrising,Vincent van der Noort,Paul Hamberg,Jules L.L.M. Coenen,Maureen J. Aarts,Inge M. van Oort,Alfons J.M. van den Eertwegh,Maartje Los,H. Pieter van den Berg,Hans Gelderblom,Suzan Vrijaldenhoven,Emile D. Kerver,Theo van Voorthuizen,Igle J. de Jong,John B. A. G. Haanen,Andries M. Bergman

Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer

2016

Sushil K. Badrising
Vincent van der Noort
Paul Hamberg
Jules L.L.M. Coenen
Maureen J. Aarts
Inge M. van Oort
Alfons J.M. van den Eertwegh
Maartje Los
H. Pieter van den Berg
Hans Gelderblom
Suzan Vrijaldenhoven
Emile D. Kerver
Theo van Voorthuizen
Igle J. de Jong
John B. A. G. Haanen
Andries M. Bergman

Objective: To evaluate the efficacy of enzalutamide (Enz) as fourth- or fifth-line treatment in men with metastasized castration-resistant prostate cancer (mCRPC)

Keywords:

Cabazitaxel
Pathology
Medicine
Castration
Prostate cancer
Cancer research
Mitoxantrone
Oncology
Internal medicine
Chemotherapy
Docetaxel
Enzalutamide
Radium-223
Abiraterone acetate
Retrospective cohort study

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations